Day Two

Saturday, 9 December

Below is a summary of the session timetable for Day Two. Greater detail for each session, including speakers and presentation titles, is given further down the page.

The third parallel session (6C, 7C and 8C) alternates between biomedical and clinical themes. Please check timings below to see when two biomedical (or clinical) sessions are happening at the same time.

Biomedical meeting Clinical meeting Biomedical/Clinical
Session 5A: Therapeutic Strategies Session 5B: Pre-approval Access  
Session 6A: SOD1 ALS: From Pathology to Therapy Session 6B: Respiratory Assessment and Management Session 6C: Biofluid Markers
Session 7A: TDP-43 Session 7B: Epidemiology Session 7C: Emerging Markers
Session 8A: Genetics Session 8B: Disease Management Session 8C: Neuroimaging
     
Poster Session B
Biomedical MeetingClinical meetingBiomedical/Clinical meeting
Session 5A: 08.30 - 10.00
THERAPEUTIC STRATEGIES
08.30 – 09.00 Antisense oligonucleotide-based therapies for motor neuron diseases F Bennett (USA)
09.00 – 09.30 Improving drug access to the CNS S Moore (USA)
09.30 – 09.45 Harnessing machine learning and artificial intelligence to identify novel ALS therapeutics M Stopford (UK)
09.45 – 10.00 Meta-analysis of pharmacogenetics interactions in ALS clinical trials R van Eijk (Netherlands)
Session 6A: 10.30 - 12.30
SOD1 ALS: FROM PATHOLOGY TO THERAPY
10.30 – 10.50 The familial G93A SOD1 mutation alters intrinsic electrical properties and morphological development of cortical interneurons R Clark (Australia)
10.50 – 11.10 Misfolded SOD1 pathology in sporadic ALS B Paré (Canada)
11.10 – 11.30 Distinct neuronal inclusions containing misfolded SOD1 in patients with mutations in C9ORF72 and other ALS- and FTD-associated genes K Forsberg (Sweden)
11.30 – 11.50 Development of peptides that specifically recognize misfolded SOD1 proteins in ALS E Tokuda (Japan)
11.50 – 12.10 Peptide-directed selective knockdown of misfolded SOD1 as a therapy for ALS J Kong (Canada)
12.10 – 12.30 A promising small molecule lead in the search for a SOD1-targeted drug for ALS G Wright (UK)
Session 7A: 14.00 - 15.30
TDP-43
14.00 – 14.20 Dynamic polymerization of TDP-43 in health and disease M Polymenidou (Switzerland)
14.00 – 14.25 TDP-43 splicing repression: Target identification and validation P Wong (USA)
14.25 – 14.50 A bona fide TDP-43 knock-in mouse demonstrates perturbed TDP-43 regulation and helps yield candidate suppressors of cognitive dysfunction in ALS-FTD J Sreedharan (UK)
14.50 – 15.10 Low expression of mutant Ubiquilin-2 exacerbates ALS-FTD features in a TDP-43 mouse model V Picher-Martel (Canada)
15.10 – 15.30 Unregulated expression of TDP-43 leads to divergent neurodegeneration in cortex and spinal cord in mice Z Xu (USA)
Session 8A: 16.00 - 17.40
GENETICS
16.00 – 16.20 Characterisation of a novel ALS-associated candidate gene identified from whole exome sequencing C Shaw (UK)
16.20 – 16.40 Targeted genetic screen of RNA-binding proteins in ALS reveals novel genetic variants with synergistic effect on clinical phenotype J Cooper-Knock (UK)
16.40 – 16.55 Integrating copy number analysis with structural variation detection in whole genome sequenced ALS UK cohort A Al-Chalabi (UK)
16.55 – 17.10 Genome wide association study of genetic modifiers in ALS carriers of repeat expansions in C9orf72 gene I Fogh (UK)
17.10 – 17.25 DNA methylation age-acceleration is associated with disease duration and age at onset in C9orf72 patients E Rogaeva (Canada)
17.25 – 17.40 Discovery of previously unknown relationships between ALS patients increases power to identify causal disease genes K Williams (Australia)
Session 5B: 8.30 - 10.00
PRE-APPROVAL ACCESS
08.30 – 08.55 Compassionate use of unapproved medicines: Law, ethics and policy A Bateman-House (USA)
08.55 – 09.20 Improving access to investigational treatment: It’s not about the FDA J Rabourn (USA)
09.20 – 09.45 Neurologists’ views on ‘Right to Try’: Salem Witch Trials revisited R Bedlack (USA)
09.45 – 10.00 Discussion
Session 6B: 10.30 - 12.30
RESPIRATORY ASSESSMENT AND MANAGEMENT
10.30 – 10.50 Characterization of ALS patients based on MIP and FVC at first visit K Akkineni (USA)
10.50 – 11.10 Comparison between slow and forced vital capacities on survival prediction in ALS S Pinto (Portugal)
11.10 – 11.30 How good is the respiratory subscore of ALSFRS-R? N Thakore (USA)
11.30 – 11.50 Cough assist using the flow and pressure graphics to improve patient outcomes J Nilsestuen (USA)
11.50 – 12.10 Mechanical insufflation exsufflation and lung volume recruitment in ALS: A prospective study of the prescription process, the outcomes and the experience R McConnell (Ireland)
12.10 – 12.30 A US randomized trial of DPS in ALS: The outcome differs from two European trials J Katz (USA)
Session 7B: 14.00 - 15.30
EPIDEMIOLOGY
14.00 – 14.20 Presymptomatic lifestyle classified according to C9orf72 genotype H Westeneng (Netherlands)
14.20 – 14.40 Genetic mutations shorten the multistep process in ALS A Chiò (Italy)
14.40 – 15.00 ALS and food intake in Italy E Pupillo (Italy)
15.00 – 15.15 The effects of duration and intensity of cigarette smoking on the risk of ALS S Peters (Netherlands)
15.15 – 15.30 Spatial analysis of ALS cases in the United States and their proximity to multidisciplinary ALS clinics, 2013 K Horton (USA)
17.25 - 17.45 Discussion
Session 8B: 16.00 - 17.40
DISEASE MANAGEMENT
16.00 – 16.20 NEALS Bulbar Subcommittee: Protocol design for speech and swallowing G Pattee (USA)
16.20 – 16.40 The Oral Secretion Scale (OSS) predicts tolerance of noninvasive ventilation (NIV), the need for hospice or transition to tracheostomy ventilation (TV) and prognostic factors for survival in patients with ALS/MND P Cazzolli (USA)
16.40 – 17.00 Trial of resistance and endurance exercise in ALS N Maragakis (USA)
17.00 – 17.20 The 100 collars project: A multi-centre evaluation of the HeadUp cervical orthosis C McDermott (UK)
17.20 – 17.40 Treatment for cramps in ALS/MND: An updated Cochrane review B Oskarsson (USA)
Session 6C: 10.30 - 12.30
BIOFLUID MARKERS
10.30 – 10.50 Urinary p75 neurotrophin receptor extracellular domain: A biomarker relevant to ALS therapy development M Rogers (Australia)
10.50 – 11.10 Blood and CSF neurofilament levels as biomarkers of pre-symptomatic disease M Benatar (USA)
11.10 – 11.30 CSF pNfH as a diagnostic and prognostic biomarker in ALS: Experience with a colorimetric sandwich immunoassay E Gray (UK)
11.30 – 11.50 Lipidomics reveals cerebrospinal-fluid signatures of ALS H Blasco (France)
11.50 – 12.10 Unravelling phenotypic heterogeneity in ALS using quantitative proteomics: From animal models of the disease to human pathology A Malaspina (UK)
12.10 – 12.30 Longitudinal analysis of the CSF proteome in ALS: Emerging microglial markers A Thompson (UK)
Session 7C: 14.00 - 15.30
EMERGING MARKERS
14.00 – 14.20 Imaging denervation in ALS for clinical trials: A longitudinal cohort study T Jenkins (UK)
14.20 – 14.40 Cortical excitability index: A novel diagnostic biomarker in ALS N Geevasinga (Australia)
14.40 – 15.00 Cortical dysfunction appears to be a regional feature in ALS P Menon (Australia)
15.00 – 15.15 Metabolic changes in asymptomatic C9orf72 carriers compared with non-carriers in the same family assessed by brain 7T MRSI H Westeneng (Netherlands)
15.15 – 15.30 The metabolic signature of ApoE genotype in ALS: A 18F-FDG-PET study A Chiò (Italy)
Session 8C: 16.00 - 17.40
NEUROIMAGING
16.00 – 16.20 Tracing disease progression in ALS: A multimodal longitudinal imaging study of structural brain involvement R Walhout (Netherlands)
16.20 – 16.40 Patterns of cortical atrophy in ALS and implications on prognosis M Rafiq (UK)
16.40 – 17.00 Perfusion imaging signatures of pathological spread across TDP-43 proteinopathies P Ferraro (USA)
17.00 – 17.20 Spinal cord gray matter atrophy as MRI biomarker for ALS patients PF Pradat (Canada)
17.20 – 17.40 Hypothalamic structure alterations in presymptomatic and symptomatic ALS M Gorges (Germany)
Day 1 Programme

Day One

Friday, 8 December

Day 2 Programme

Day Two

Saturday, 9 December

Day 1 Programme

Day Three

Sunday, 10 December